The Role of Benzoyl Peroxide in the New Treatment Paradigm for Acne

June 2013 | Volume 12 | Issue 6 | Supplement Individual Articles | 73 | Copyright © June 2013

Leon H. Kircik MD

Mount Sinai Medical Center, New York, NY
Indiana University School of Medicine, Indianapolis, IN
Physicians Skin Care, PLLC, Louisville, KY


As concerns about antibiotic resistance have continued to evolve, so has the management of various diseases, including acne vulgaris. The use of BP, especially in combination with topical antibacterials such as clindamycin, has emerged as an important strategy for reducing the risk of developing bacterial resistance. However, data suggest that the potent bactericidal effects of BP can quickly diminish P acnes colonization without the need for the use of additional topical antibiotic. Using BP in conjunction with a topical retinoid such as adapalene rather than in combination with an antibiotic may be a reasonable treatment strategy. The once-daily fixed combination formulation of adapalene 0.1% and BP 2.5% is a proven effective, convenient option for acne management that targets multiple aspects of the pathogenesis of acne. Therefore, we may have to reconsider the role of topical antibiotics such as clindamycin in the new treatment paradigm of acne.


Dr. Kircik has served as an advisor, investigator, consultant, and speaker for Galderma, Allergan, Bayer, LeoPharma, Promius Pharma, Quinnova, Stiefel/GSK, Taro, Valeant, and Warner Chilcott.


  1. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8(1):41-45.
  2. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;4(12):813-831.
  3. Nishijima S, Akamatsu H, Akamatsu M, Kurokawa I, Asada Y. The antibiotic susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne. J Dermatol. 1994;21(3):166-171.
  4. Price MF, McBride ME, Wolf JE Jr. Prevalence of methicillin-resistant Staphylococcus aureus in a dermatology outpatient population. South Med J. 1998;91(4):369-371.
  5. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148(4):249-257.
  6. Retapamulin Global Surveillance Study. Data on file. GlaxoSmithKline; Collegeville, PA, USA.
  7. Grohmann E, Muth G, Espinosa M. Conjugative plasmid transfer in gram-positive bacteria. Microbiol Mol Biol Rev. 2003;67(2):277-301.
  8. Dionisio F, Matic I, Radman M, Rodrigues OR, Taddei F. Plasmids spread very fast in heterogeneous bacterial communities. Genetics. 2002;162(4):1525-1532.
  9. Horaud T, Le Bouguenec C, Pepper K. Molecular genetics of resistance to macrolides, lincosamides and streptogramin B (MLS) in streptococci. J Antimicrob Chemother. 1985;16(suppl A):s111-s135.
  10. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem Pharmacol. 2000;60(4):457-470.
  11. Nishijima S, Kurokawa I, Katoh N, Watanabe K. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J Dermatol. 2000;27(5):318-323.
  12. Dreno B, Reynaud A, Moyse D, Habert H, Richet H. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol. 2001;11(6):549-553.
  13. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003;139(4):467-471.
  14. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):s1-s37.
  15. Thiboutot D, Gollnick H, Bettoli V, et al; Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(suppl 5):s1-s50.
  16. IMS Health, National Prescription Audit Plus, Year 2005, data extracted March 2006. Fairfield, CT: IMS Health.
  17. Shaheen B, Gonzalez M. A microbial aetiology of acne: what is the evidence? Br J Dermatol. 2011;165(3):474-485.
  18. Kim J. Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology. 2005;211(3):193-198.
  19. Goulden V. Guidelines for the management of acne vulgaris in adolescents. Paediatr Drugs. 2003;5(5):301-313.
  20. Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin. 2009;27(1):33-42.
  21. Leyden JJ. The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg. 2001;20(3):139-143.
  22. Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;8:CD002086.
  23. Warner GT, Plosker GL. Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne. Am J Clin Dermatol. 2002;3(5):349-360.
  24. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24(7):1117-1133.
  25. Pariser D, Bucko A, Fried R, et al. Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimen. J Drugs Dermatol. 2010;9(7):805-813.
  26. Brodell RT, Schlosser BJ, Rafal E, et al. A fixed-dose combination of adapalene 0.1%-BP 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. J Dermatolog Treat. 2012;23(1):26-34.
  27. Gold LS, Tan J, Cruz-Santana A, et al. A North American study of adapalene- benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84(2):110-116.
  28. Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol. 1995;132(2):204-208.
  29. Lee WL, Shalita AR, Poh-Fitzpatrick MB. Comparative studies of porphyrin production in Propionibacterium acnes and Propionibacterium granulosum. J Bacteriol. 1978;133(2):811-815.
  30. Pagnoni A, Kligman AM, Kollias N, Goldberg S, Stoudemayer T. Digital fluorescence photography can assess the suppressive effect of benzoyl peroxide on Propionibacterium acnes. J Am Acad Dermatol. 1999;41(5 Pt 1):710-716.
  31. Leyden JJ, Preston N, Osborn C, Gottschalk RW. In-vivo effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on antibiotic-sensitive and resistant Propionibacterium acnes. J Clin Aesthet Dermatol. 2011;4(5):22-26.


Leon H. Kircik